7xm moto

7xm moto SAY the name JK Rowling and be ready to take cover as sanctimonious snowflakes screech hate about her views on transgender people. But attempts by leftie woke warriors to cancel the Harry Potter author have failed, with news she will definitely play a key role in a £1.6billion, ten-year TV adaptation of her books about the boy wizard. Furious trans activists had complained about Rowling being an executive producer on the show, which is being made in Britain for American TV channel HBO’s streaming service Max. Rowling has previously come under fire for claiming the “trans women are women” mantra is “idiotic”, and for campaigning to preserve safe spaces and women’s toilets for biological females only. JK Rowling has a right to express her personal views. We will remain focused on the development of the new series, which will only benefit from her involvement. But she denies being transphobic — and now excitement about the new TV project has drowned out calls for a boycott of her participation. At the weekend, HBO said: “We are proud to once again tell the story of Harry Potter — the heartwarming books that speak to the power of friendship, resolve and acceptance. READ MORE ON JK ROWLING “JK Rowling has a right to express her personal views. “We will remain focused on the development of the new series, which will only benefit from her involvement.” The announcement has quietened those who have lined up to deny the 59-year-old her views on transgender questions. Daniel Radcliffe and Rupert Grint , stars of the Harry Potter movie franchise, have previously slammed her comments on transgender rights. Most read in News TV Casting open to public But Daniel, who played Harry, and Rupert, famed as Potter’s pal Ron Weasley at wizard school Hogwarts, have now both said they are looking forward to HBO bringing back the characters they played in eight films. And well they might — the TV series, which promises to “dive deep into each one of the iconic books” is a seriously big deal. Thousands of children have auditioned to play Harry, Ron and their friend Hermione Granger — portrayed in the films by Emma Watson — ahead of the expected start of filming in the spring . Meanwhile, Gary Oldman , who played wizard Sirius Black in the movies, has put his hat in the ring for future projects, saying, “Maybe in a few years I can play [Hogwarts headmaster] Dumbledore”. His former fellow cast members, including Helena Bonham Carter , Ralph Fiennes and Jim Broadbent , have all defended Rowling’s right to express her opinions. If there’s a better hill to die on than the rights and safety of women and children, I’ve never found it. These public displays of support for the writer reflect a shift in Holly-wood, which appears to be tiring of political correctness, which has proven to be a turn-off at the box office. Four years ago when Rowling mocked “people who menstruate” as a term to describe “women”, she faced a huge backlash from stars including Emma Watson. But rather than be cowed by the criticism, JK has continued to stand up for her beliefs. Last week she posted defiantly: “If there’s a better hill to die on than the rights and safety of women and children, I’ve never found it.” The appeal of the story of orphan schoolboy Harry who discovers he has magical powers appears to be just as strong as ever. Since the first novel was published in 1997, and followed by six sequels, more than 600million books have been sold across the world. Shops selling merchandise, such as scarves and wands, continue to open and next month streaming platform Amazon Prime Video launches a Great British Bake Off-style TV show titled Harry Potter: Wizards Of Baking. When anti-Rowling campaigners called for a boycott of the Hogwarts Legacy video game last year, their protest had little or no effect as sales soared past 12million in just a couple of months. Meanwhile, stage play Harry Potter And The Cursed Child is still going strong in London’s West End after eight years. It is no surprise, then, that HBO parent company Warner Bros, whose eight Harry Potter films made around £ 7 billion combined, was keen to return to the Hogwarts school of Witch-craft and Wizardry. The movie giant’s streaming channel Max, previously known as HBO Max, will air the TV series in 2026. Succession and Killing Eve producer Francesca Gardiner will lead the project with British director Mark Mylod, whose CV includes Game Of Thrones . There are rumours Brit actor Mark Rylance, star of BBC period drama Wolf Hall, is in line to play Hogwarts Professor Albus Dumbledore . In September it was announced that the casting process for all the young Hogwarts characters — from Harry to his nemesis and fellow wizarding student Draco Malfoy — would be open to the public. They are looking for talented kids aged nine to 11 who live in the UK or Ireland . No acting experience is necessary, although show bosses have also been scouting stage schools . The website taking applications has now closed due to the huge response. It is a massive boost for the British TV industry, with the bulk of the series set to be made at Warner Bros’ studios in Leavesden, near Watford. The budget for each of the ten seasons is reckoned to be around £159million and the plan is to film each series back to back because bosses do not want the cast to age too much on screen. But it will be tricky because there are strict regulations about the hours school-age actors and actresses are allowed to work. Daniel Radcliffe, now aged 35, who had the most scenes in the Potter movies, had to be taught on set between shoots. He earned a reported £86million from the films but it is unlikely any of the wannabe Harrys eyeing up the TV gig would enjoy the same sort of payday. Daniel has backed the remake, saying: “It’ll be cool to see the torch get passed on.” Rupert Grint agrees, telling GQ magazine: “I’d love to see Harry Potter be adapted into a TV show. “It would really work.” Rowling, who is worth an estimated £945million, retains the rights to her books and she has always insisted strongly on having her say about any Potter-related projects. It was thanks to the Gloucestershire-born author, who now lives in Scotland , that the movies were not Americanised. HBO and Max chairman and CEO Casey Bloys says Rowling has been “very, very involved in the process of selecting the writer and director” for the telly series. Bloys also denied that her comments about trans issues had “affected the casting or hiring of writers or production staff”. Indeed, Warner Bros are not the only ones who wish to work with the hugely imaginative writer. Even though the BBC twice apologised last year after Rowling was described during its programmes as “anti-trans”, the corporation keep adapting her Cormoran Strike crime novels into TV shows. Activists are trying to organise yet another boycott of my work, this time of the Harry Potter TV show. As forewarned is forearmed, I’ve taken the precaution of laying in a large stock of champagne. This December, her fictional detective played by Tom Burke will return for a BBC One four-part dramatisation of her 2022 novel The Ink Black Heart. Meanwhile, plenty of actors are backing JK. Broadbent, who played Hogwarts’ Professor Horace Slug-horn in two Potter films, said, “JK Rowling is amazing”, and Bonham Carter, who portrayed evil Bellatrix Lestrange, commented: “She has been hounded.” Fiennes, who played Lord Voldemort, described the attacks on the author as “appalling”, and Evanna Lynch, witch Luna Love-good in the films, said: “I do wish people would just give her more grace and listen to her.” But this type of comment is at odds with much of Gen Z. Not that JK is too worried about being cancelled, as she just shrugs if all off. READ MORE SUN STORIES Last April she said: “Activists are trying to organise yet another boycott of my work, this time of the Harry Potter TV show. “As forewarned is forearmed, I’ve taken the precaution of laying in a large stock of champagne.” By Julie Bindel, feminist and friend of JK Rowling JK ROWLING’S pinned tweet, in response to a trans activist claiming he burns her books and toasts marshmallows over the flame, reads: “I get the same royalties whether you read them or burn them. Enjoy your marshmallows!” Having bullied the majority into submission for so long, these activists are now losing ground. Increasingly, they are ignored and sidelined. Rowling is a feminist hero. Since first speaking out against the crazed gender ideology that has swept much of the world, including treasured institutions, she has made an immeasurable difference to women and girls everywhere. As one of the most famous authors ever, Rowling had no need to take a stand on this contentious, toxic issue – she did it because she could not remain silent. Having spent millions supporting orphaned children and other disadvantaged groups through her charitable work, she decided that adding her voice to the fight against those determined to see an end to female-only spaces and facilities would be worth the inevitable backlash. And what a backlash: in addition to innumerable rape and death threats, she has been publicly maligned by those whose fame and fortune she helped create. The actors who played Harry, Ron and Hermione have all stuck the knife in. As a lesbian, and as someone lucky enough to be able to call Rowling a personal friend, I know their claims are utter fabrication. Calls to boycott the new HBO Harry Potter TV series is nothing but bullying and posturing. I don’t know how those responsible sleep at night, when the ideology Rowling speaks out against leads to children being unnecessarily medicalised for life. Asked by a trans activist why she wanted to “die on this hill”, Rowling replied in her usual forthright manner: “If there’s a better hill to die on than the rights and safety of women and children, I’ve never found it.”

Castellum, Inc. Announces Proposed Public Offering Of Common StockFLORENCE, Italy & BARCELONA, Spain--(BUSINESS WIRE)--Dec 11, 2024-- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, along with MEDSIR, a leading global independent clinical research company in oncology and part of Oncoclínicas & Co., the largest specialized oncology treatment group in Latin America, presented research on the pioneering clinical trial ADELA. This important research addresses therapeutic resistance in advanced ER+/HER2- breast cancer. Presented at the San Antonio Breast Cancer Symposium 2024 (SABCS), the study represents a key milestone in the quest for more effective and personalized treatment options for patients with disease progression. The standard first-line treatment for advanced ER+/HER2- breast cancer combines endocrine therapy with CDK4/6 inhibitors. ESR1 mutations develop as a result of prior exposure to endocrine therapy during metastatic treatment, and up to 50% of ER+, HER2- advanced or metastatic breast cancers will develop these mutations. ESR1 mutations cause the tumors to become resistant to endocrine therapy, in turn causing the cancer to progress; therefore, it is important to test for ESR1 whenever mBC progresses. Longer exposure to endocrine therapy during first-line treatment increases the chance of a patient’s tumor developing an ESR1 mutation. With the goal of addressing this unmet medical need, the ADELA phase III clinical trial investigates a new therapeutic option combining elacestrant, a next generation, oral selective estrogen receptor degrader, with everolimus, an mTORC1 inhibitor. This combination is being evaluated in patients with advanced ER+/HER2- breast cancer that harbors ESR1 mutations, and who have experienced progression after standard first-line treatment. Results from the phase III EMERALD study were the basis for elacestrant’s approval. Meanwhile, everolimus has shown efficacy in inhibiting other resistance mechanisms in this type of cancer. The elacestrant and everolimus combination has demonstrated preliminary efficacy with a manageable safety profile in the phase 1b/2 ELEVATE study ( NCT05563220 ). “We at Menarini Stemline are delighted to announce the collaboration with MEDSIR to continue advancing the clinical research to explore the combination therapy with elacestrant,” said Nassir Habboubi, MD, Chief Medical Officer of Stemline Therapeutics. “We are committed to driving innovation in cancer treatment by delivering transformational therapies aiming to extend the lives of people living with cancer.” The primary objective of this international, randomized, double-blind trial is to evaluate whether the combination of elacestrant and everolimus offers greater efficacy in delaying disease progression compared to elacestrant monotherapy. Additionally, it investigates other crucial aspects, such as overall survival, toxicity profile, and the impact on patients’ quality of life. The ADELA study represents a critical step in understanding how to overcome tumor resistance challenges in patients with ESR1 mutations, with the goal of advancing towards more effective and safer treatments. “At MEDSIR, we understand innovation not only as achieving clinical results but as the ability to transform patients' lives on a global scale. With ADELA, we take a decisive step toward accomplishing less invasive and more accessible treatments, aiming to offer new hope to those facing the most complex forms of the disease. This advancement reinforces our commitment to increasingly personalized and patient-centered medicine, a fundamental pillar in shaping the future of oncology,” said Dr. Antonio Llombart-Cussac, Senior Scientific Leader at MEDSIR. The phase III study not only has significant clinical objectives, but also holds the potential to pave the way for regulatory approval of this therapeutic combination, enabling its use in a broader population of patients with advanced breast cancer. Moreover, the international scope of the study, which includes participation from multiple countries, including Spain, Italy, France, Austria, the Czech Republic, Greece, Germany, and the United Kingdom, underscores the study’s global importance and relevance in the scientific community. The presentation of the ADELA study at an event as prominent as SABCS 2024 reinforces MEDSIR’s leadership in excellence-driven oncology research and highlights its focus on addressing unmet needs in breast cancer treatment. The ADELA study is active and already recruiting patients. About ORSERDU (elacestrant) U.S. Indication: ORSERDU (elacestrant), 345 mg tablets, is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Full prescribing information for the U.S. can be found at www.orserdu.com . Important Safety Information Warning and Precautions Dyslipidemia : Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively. Monitor lipid profile prior to starting and periodically while taking ORSERDU. Embryo-Fetal Toxicity : Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the final dose. Adverse Reactions Serious adverse reactions occurred in 12% of patients who received ORSERDU. Serious adverse reactions in >1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each). The most common adverse reactions (≥10%) , including laboratory abnormalities, of ORSERDU were musculoskeletal pain (41%), nausea (35%), increased cholesterol (30%), increased AST (29%), increased triglycerides (27%), fatigue (26%), decreased hemoglobin (26%), vomiting (19%), increased ALT (17%), decreased sodium (16%), increased creatinine (16%), decreased appetite(15%), diarrhea(13%), headache (12%), constipation (12%), abdominal pain (11%), hot flush (11%), and dyspepsia (10%). Drug interactions Concomitant use with CYP3A4 Inducers and/or inhibitors : Avoid concomitant use of strong or moderate CYP3A4 inhibitors with ORSERDU. Avoid concomitant use of strong or moderate CYP3A4 inducers with ORSERDU. Use in specific populations Lactation : Advise lactating women to not breastfeed during treatment with ORSERDU and for 1 week after the last dose. Hepatic Impairment : Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of ORSERDU in patients with moderate hepatic impairment (Child-Pugh B). The safety and effectiveness of ORSERDU in pediatric patients have not been established. To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . About The Menarini Group The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $4.7 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide. For further information, please visit www.menarini.com . About Stemline Therapeutics Inc. Stemline Therapeutics, Inc. (“Stemline”) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes ORSERDU ® (elacestrant) in the U.S. and Europe, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline also commercializes ELZONRIS ® (tagraxofusp-erzs), a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States and Europe, which is the only approved treatment for BPDCN in the U.S. and E.U. to date. Stemline also commercializes NEXPOVIO ® (selinexor) in Europe, an XPO1 inhibitor for multiple myeloma. Stemline also has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers. About MEDSIR Established in 2012, MEDSIR prides itself on working closely with its strategic partners to drive innovation in oncology research. Operating in Spain and the United States, the company provides end-to-end clinical trial management, from study design to publication, with an extensive global network of experts and integrated technology to streamline the process. The company offers proof-of-concept support and a strategic approach that enables research partners to benefit from the best of both worlds: industry clinical research and investigator-driven trials. With the aim of promoting independent research worldwide, MEDSIR has formed a strategic alliance with Oncoclínicas, the leading oncology group in Brazil, which offers outstanding research potential in South America. For further information: www.medsir.org About Oncoclínicas & CO Oncoclínicas&Co is the largest group dedicated to cancer treatment in Latin America, with a specialized and innovative model focused on the entire oncology care journey, combining operational efficiency, humanized care, and high specialization through a medical team composed of over 2,700 specialist physicians with an emphasis on oncology. With its mission to democratize cancer treatment, it offers a comprehensive system that integrates outpatient clinics with high-complexity cancer centers. The company operates 145 units across 39 Brazilian cities, allowing high-quality access in all regions it serves, aligned with world-class standards. Focusing on technology, precision medicine, and genomics, Oncoclínicas performed approximately 635,000 treatments in 2023. It is the exclusive partner in Brazil of the Dana Farber Cancer Institute, affiliated with Harvard Medical School, one of the world’s leading cancer research and treatments centers. The company also owns Boston Lighthouse Innovation, a bioinformatics firm based in Cambridge, United States, and holds shares in Medsir, a company dedicated to the development and management of clinical trials for independent cancer research, based in Barcelona, Spain. Recently, Oncoclínicas expanded its operations to Saudi Arabia through a joint venture with the Al Faisaliah Group, bringing its mission to beat cancer to a new continent and providing advanced oncology care on a global scale by combining oncological hyperspecialization with innovative treatment approaches. The company is part of the IDIVERSA index, launched by B3, highlighting companies committed to gender and racial diversity. For more information, visit: www.grupooncoclinicas.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20241211008868/en/ CONTACT: Media Contacts The Menarini Group Valeria Speroni Cardi Email:pressoffice@menarini.comStemline Therapeutics, Inc. Cheya Pope Email:media@menarinistemline.comGlobal Brand Communication MEDSIR: Sergio Aguilar Global Brand & Communication Director +34 674 82 87 24 sergio.aguilar@medsir.orgEduardo Martín Espallargas Global Communication & Marketing Manager +34 634 835 389 Eduardo.martin@medsir.orgCarles Berloso Cortés International PR & Comms +34 677 49 75 23 carles.berloso@medsir.org KEYWORD: TEXAS SPAIN NORTH AMERICA UNITED STATES EUROPE ITALY INDUSTRY KEYWORD: RESEARCH CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE ONCOLOGY SOURCE: The Menarini Group Copyright Business Wire 2024. PUB: 12/11/2024 06:35 PM/DISC: 12/11/2024 06:35 PM http://www.businesswire.com/news/home/20241211008868/enProsecutors said Monday they have requested an arrest warrant for former Defense Minister Kim Yong-hyun to investigate his alleged role in President Yoon Suk Yeol's short-lived declaration of martial law last week. The special prosecution investigation team summoned Kim earlier in the day for questioning on treason, abuse of power and other charges, marking the third interrogation since his emergency arrest the previous day. Prosecutors said they are seeking the warrant over concerns that Kim, a key suspect who proposed martial law to Yoon, might attempt to flee or tamper with evidence, given that he changed his mobile phone after the martial law announcement Tuesday night. He allegedly masterminded the declaration of a martial law decree banning all political activities as well as the infiltration by military forces into the National Assembly and the offices of the National Election Commission following Yoon's declaration. Kim reportedly conceded during questioning that he proposed martial law to Yoon but claimed that his actions were neither illegal nor unconstitutional. (Yonhap)

'The better team won tonight' - Ronan O'Gara delighted with La Rochelle victory over Bath

Got nine bucks? You could be going to a Blue Jays gameStock market today: Wall Street hits more records following a just-right jobs report

Stocks wavered on Wall Street in afternoon trading Thursday, as gains in tech companies and retailers helped temper losses elsewhere in the market. The S&P 500 was down less than 0.1% after drifting between small gains and losses. The benchmark index is coming off a three-day winning streak. The Dow Jones Industrial Average was up 6 points, or less than 0.1%, as of 1:52 p.m. Eastern time. The Nasdaq composite was down less than 0.1%. Trading volume was lighter than usual as U.S. markets reopened after the Christmas holiday. Chip company Broadcom rose 2.9%, Micron Technology was up 1% and Adobe gained 0.8%. While tech stocks overall were in the green, some heavyweights were a drag on the market. Semiconductor giant Nvidia, whose enormous valuation gives it an outsize influence on indexes, slipped 0.1%. Meta Platforms fell 0.7%, Amazon was down 0.6%, and Netflix gave up 1.1%. Tesla was among the biggest decliners in the S&P 500, down 1.9%. Health care stocks helped lift the market. CVS Health rose 1.7% and Walgreens Boots Alliance rose 3% for the biggest gain among S&P 500 stocks. Several retailers also gained ground. Target rose 2.8%, Best Buy was up 2.2% and Dollar Tree gained 2.7%. Retailers are hoping for a solid sales this holiday season, and the day after Christmas traditionally ranks among the top 10 biggest shopping days of the year, as consumers go online or rush to stores to cash in gift cards and raid bargain bins. U.S.-listed shares in Honda and Nissan rose 4% and 16%, respectively. The Japanese automakers announced earlier this week that the two companies are in talks to combine. Traders got a labor market update. U.S. applications for unemployment benefits held steady last week , though continuing claims rose to the highest level in three years, the Labor Department reported. Treasury yields turned mostly lower in the bond market. The yield on the 10-year Treasury fell to 4.57% from 4.59% late Tuesday. Major European markets were closed, as well as Hong Kong, Australia, New Zealand and Indonesia. Trading was expected to be subdued this week with a thin slate of economic data on the calendar. Still, U.S. markets have historically gotten a boost at year’s end despite lower trading volumes. The last five trading days of each year, plus the first two in the new year, have brought an average gain of 1.3% since 1950. So far this month, the U.S. stock market has lost some of its gains since President-elect Donald Trump’s win on Election Day, which raised hopes for faster economic growth and more lax regulations that would boost corporate profits. Worries have risen that Trump’s preference for tariffs and other policies could lead to higher inflation , a bigger U.S. government debt and difficulties for global trade. Even so, the U.S. market remains on pace to deliver strong returns for 2024. The benchmark S&P 500 is up roughly 26% so far this year and remains near its most recent all-time high it set earlier this month — its latest of 57 record highs this year. Wall Street has several economic reports to look forward to next week, including updates on pending home sales and home prices, a report on U.S. construction spending and snapshots of manufacturing activity. AP Business Writers Elaine Kurtenbach and Matt Ott contributed.Rape allegation against Jay-Z won’t impact NFL's relationship with music mogul, Goodell saysInvestors with a lot of money to spend have taken a bullish stance on Affirm Holdings AFRM . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AFRM, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga 's options scanner spotted 15 uncommon options trades for Affirm Holdings. This isn't normal. The overall sentiment of these big-money traders is split between 53% bullish and 46%, bearish. Out of all of the special options we uncovered, 6 are puts, for a total amount of $736,660, and 9 are calls, for a total amount of $527,916. Projected Price Targets Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $85.0 for Affirm Holdings over the recent three months. Volume & Open Interest Development Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Affirm Holdings's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Affirm Holdings's substantial trades, within a strike price spectrum from $30.0 to $85.0 over the preceding 30 days. Affirm Holdings 30-Day Option Volume & Interest Snapshot Largest Options Trades Observed: Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume AFRM PUT SWEEP BULLISH 03/21/25 $12.95 $12.85 $12.85 $72.50 $257.0K 89 201 AFRM PUT TRADE BULLISH 01/17/25 $4.5 $4.45 $4.45 $67.50 $165.0K 460 734 AFRM PUT TRADE BULLISH 01/15/27 $23.7 $23.45 $23.45 $67.50 $147.7K 87 63 AFRM CALL TRADE BEARISH 01/17/25 $4.15 $4.1 $4.1 $68.00 $107.8K 35 590 AFRM PUT TRADE BULLISH 01/17/25 $4.45 $4.4 $4.4 $67.50 $89.3K 460 246 About Affirm Holdings Affirm Holdings Inc offers a platform for digital and mobile-first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a majority share of its revenue from the United States. In light of the recent options history for Affirm Holdings, it's now appropriate to focus on the company itself. We aim to explore its current performance. Present Market Standing of Affirm Holdings Trading volume stands at 1,961,133, with AFRM's price up by 1.97%, positioned at $67.19. RSI indicators show the stock to be is currently neutral between overbought and oversold. Earnings announcement expected in 42 days. Professional Analyst Ratings for Affirm Holdings In the last month, 5 experts released ratings on this stock with an average target price of $77.4. Turn $1000 into $1270 in just 20 days? 20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access .* In a positive move, an analyst from JMP Securities has upgraded their rating to Market Outperform and adjusted the price target to $78. * Consistent in their evaluation, an analyst from Deutsche Bank keeps a Hold rating on Affirm Holdings with a target price of $75. * Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Affirm Holdings with a target price of $74. * An analyst from Goldman Sachs persists with their Buy rating on Affirm Holdings, maintaining a target price of $78. * An analyst from Jefferies has elevated its stance to Buy, setting a new price target at $82. Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Affirm Holdings with Benzinga Pro for real-time alerts. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Daniel Cormier pitches a fresh challenge for Sean O’Malley’s UFC comeback fight after losing the bantamweight title

Slower AI spending could ignite a ‘vicious’ downturn for chipmakers, Nvidia supplier saysAP Business SummaryBrief at 6:46 p.m. ESTOMAHA, Neb. (AP) — Investor Warren Buffett renewed his Thanksgiving tradition of giving by handing out more than $1.1 billion of Berkshire Hathaway stock to four of his family's foundations Monday, and he offered new details about who will be handing out the rest of his fortune after his death. Buffett has said previously that his three kids will distribute his remaining $147.4 billion fortune in the 10 years after his death, but now he has also designated successors for them because it's possible that Buffett's children could die before giving it all away. He didn't identify the successors, but said his kids all know them and agree they would be good choices. “Father time always wins. But he can be fickle – indeed unfair and even cruel – sometimes ending life at birth or soon thereafter while, at other times, waiting a century or so before paying a visit,” the 94-year-old Buffett said in a letter to his fellow shareholders Monday. “To date, I’ve been very lucky, but, before long, he will get around to me. There is, however, a downside to my good fortune in avoiding his notice. The expected life span of my children has materially diminished since the 2006 pledge. They are now 71, 69 and 66.” Buffett said he still has no interest in creating dynastic wealth in his family — a view shared by his first and current wives. He acknowledged giving Howard, Peter and Susie millions over the years, but he has long said he believes “hugely wealthy parents should leave their children enough so they can do anything but not enough that they can do nothing.” The secret to building up such massive wealth over time has been the power of compounding interest and the steady growth of the Berkshire conglomerate Buffett leads through acquisitions and smart investments like buying billions of dollars of Apple shares as iPhone sales continued to drive growth in that company. Buffett never sold any of his Berkshire stock over the years and also resisted the trappings of wealth and never indulged in much — preferring instead to continue living in the same Omaha home he'd bought decades earlier and drive sensible luxury sedans about 20 blocks to work each day. “As a family, we have had everything we needed or simply liked, but we have not sought enjoyment from the fact that others craved what we had,” he said. If Buffett and his first wife had never given away any of their Berkshire shares, the family's fortune would be worth nearly $364 billion — easily making him the world's richest man — but Buffett said he had no regrets about his giving over the years. The family's giving began in earnest with the distribution of Susan Buffett's $3 billion estate after her death in 2004, but really took off when Warren Buffett announced plans in 2006 to make annual gifts to the foundations run by his kids along with the one he and his wife started, as well as the Bill & Melinda Gates Foundation. Warren Buffett's giving to date has favored the Gates Foundation with $55 billion in stock because his friend Bill Gates already had his foundation set up and could handle huge gifts when Buffett started giving away his fortune. But Buffett has said his kids now have enough experience in philanthropy to handle the task and he plans to cut off his Gates Foundation donations after his death. Buffett always makes his main annual gifts to all five foundations every summer, but for several years now he has been giving additional Berkshire shares to his family's foundations at Thanksgiving. Buffett reiterated Monday his advice to every parent to allow their families to read their will while they are still alive — like he has done — to make sure they have a chance to explain their decisions about how to distribute their belongings and answer their children's questions. Buffett said he and his longtime investing partner Charlie Munger, who died a year ago, “saw many families driven apart after the posthumous dictates of the will left beneficiaries confused and sometimes angry.” Today, Buffett continues to lead Berkshire Hathaway as chairman and CEO and has no plans to retire although he has handed over most of the day-to-day managing duties for the conglomerates dozens of companies to others. That allows him to focus on his favorite activity of deciding where to invest Berkshire's billions . One of Buffett's deputies who oversees all the noninsurance companies now, Greg Abel, is set to take over as CEO after Buffett's death. Even after converting 1,600 Class A shares into 2.4 million Class B Berkshire shares and giving them away, Buffett still owns 206,363 Class A shares and controls more than 30% of the vote.

SHOWING UP FOR SCHOOL

Pop sensation Ed Sheeran has taken to social media to apologise after accidentally gatecrashing a live interview with new Manchester United head coach Ruben Amorim. Watch selected NRL, AFL, SSN games plus every F1 qualifying session and race live in 4K on Kayo. New to Kayo? Get your first month for just $1. Limited time offer. Amorim was being interviewed on Sky Sports after United’s 1-1 draw with Ipswich, who Sheeran owns a minority stake in. Sheeran interrupted the interview to speak with analyst Jamie Redknapp, who initially greeted the singer before quickly suggesting he could “come and say hello in a minute”. Sheeran, clearly oblivious to the fact Amorim was being interviewed on live TV, posted an apology on his Instagram story on Monday morning, writing he felt like “a bit of a bell***”. “Apologies if I offended Amorim yesterday, didn’t actually realise he was being interviewed at the time, was popping to say hi and bye to Jamie,” Sheeran wrote on his Instagram story. “Obv feel a bit of a bell*** but life goes on. Great game though, congrats on all involved x”. Sheeran is a lifelong Ipswich supporter and has been a shirt sponsor for both the men’s and women’s teams since 2021. The 33-year-old bought a 1.4 percent minority stake in the club in August following their promotion to the English top flight for the first time in 22 years. Singer-songwriter Sheeran, a four-time Grammy award winner, has also found a new role at Ipswich. The club’s chairman Mark Ashton previously revealed he was even instrumental in the recruitment of one player after joining a video call with the potential signing. “A local man, global superstar, sponsor of the football club, now a shareholder and now officially part of our recruitment team,” Ashton said at a Soccerex event on Thursday. “In the summer we were trying to persuade one particular player to join the football club and realised very quickly that he was an Ed Sheeran fan. “Ed jumped on a Zoom call with him at the training ground just before he stepped on stage with Taylor Swift, hopefully that was a key part of getting the player across the line. “We’ve gone from the third tier of English football to the Premier League, but we haven’t forgotten our roots and Ed’s a key part of that, the work that we do in our local communities is central to us.” Sheeran watched Ipswich’s first game of the season against Liverpool at Portman Road and was also at Tottenham when Kieran McKenna’s team secured their first Premier League win of the campaign in November. “I have lived in Suffolk since I was three years old and, while I travel the world and sometimes feel like an outsider in big cities, Suffolk and Ipswich have always made me feel part of the community and protected,” Sheeran said earlier this year. “It’s such a joy to be a fan of Ipswich Town. There are ups and downs but football is all about taking the highs and the lows.”

Bill Clinton tells MSNBC's Joe Scarborough that 'People are losing faith in institutions'The large mysterious drones reported flying over parts of New Jersey in recent weeks appear to avoid detection by traditional methods such as helicopter and radio, according to a state lawmaker briefed Wednesday by the Department of Homeland Security. In a post on the social media platform X, Assemblywoman Dawn Fantasia described the drones as up to 6 feet in diameter and sometimes traveling with their lights switched off. The Morris County Republican was among several state and local lawmakers who met with state police and Homeland Security officials to discuss the spate of sightings that range from the New York City area through New Jersey and westward into parts of Pennsylvania, including over Philadelphia. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.Stock market today: Stocks waver in thin trading after US markets reopen following a holiday pause

Small fish, pig Pond: Lakers excited for tougher waters in Central Lakes Conference

OWINGS MILLS, Md. (AP) — Fresh off one of its best showings of the season, the Baltimore defense now has another problem to worry about. Roquan Smith missed practice again Friday because of a hamstring injury. Although the Ravens didn't officially rule him or anyone else out — they don't play until Monday night — the All-Pro linebacker's status seems dicey. “Definitely it will be a challenge if Roquan can’t go,” defensive coordinator Zach Orr said. “We’re holding out hope and everything like that. I think it’ll just be by committee. Not one person is going to replace Roquan. Roquan’s an every-down linebacker.” Although the Ravens lost 18-16 last weekend, Baltimore didn't allow a touchdown. That was an encouraging sign for a team that ranks 26th in the league in total defense. Baltimore is on the road Monday against the Los Angeles Chargers. The Ravens appear to have dodged one potential nightmare. Star safety Kyle Hamilton injured an ankle against Cincinnati on Nov. 7, but he was able to play almost every defensive snap the following week against Pittsburgh. But Smith was injured in that game and didn't practice Thursday or Friday. Linebacker Malik Harrison had a season high in tackles last weekend and figures to have a significant role if Smith can't go. “We tell these guys, ‘You’re one play away to going in there — you never know, so you got to stay ready.’ Malik — he was ready,” Orr said. “I thought he went in there and did a good job, especially after the first series, he settled down. That’s what we expect from him.” It's hard to tell whether last week can be a significant turning point for Baltimore's defense. The Ravens allowed only 10 points in a dominant win over Buffalo in Week 4, then yielded 38 against Cincinnati the following game. After allowing 10 against Denver, the Ravens were picked apart by the Bengals again a few days later. So they still haven't shown they can play a good game defensively and then build on it. “I think it’s easier said than done. It’s something that we kind of got caught up saying against Buffalo and then coming up the next week and not doing," Hamilton said. "We’re aware of it now and know that we played a good game, but I think we can get a lot better, and I think that’s kind of the mindset everybody on defense has right now.” Hamilton's ability to make a difference all over the field is part of what makes him valuable, but positioning him deep is one way the Ravens can try to guard against big passing plays. Pittsburgh's Russell Wilson threw for only 205 yards against Baltimore. That's after Joe Burrow passed for 428 and four touchdowns in the Ravens' previous game. “I’ve always seen myself as a safety. A versatile one, but at the end of the day, I think I play safety,” Hamilton said. “If I’m asked to go play safety, I feel like that’s not an issue for me to play safety if I’m a safety.” NOTES: In addition to Smith, WR Rashod Bateman (knee), DT Travis Jones (ankle), S Sanoussi Kane (ankle) C Tyler Linderbaum (back) and CB Arthur Maulet (calf) missed practice Friday. WR Nelson Agholor (illness) returned to full participation after missing Thursday's practice. AP NFL: https://apnews.com/hub/NFLNEW YORK , Dec. 6, 2024 /PRNewswire/ -- This December, Mount Sinai Hospital's Department of Urology, under the leadership of Ash Tewari, MBBS, MCh, FRCS (Hon.), DSc (Hon.), System Chair of Urology at Mount Sinai , invites you to the Sixth International Prostate Cancer Symposium and World Congress of Urologic Oncology—a four-day event that promises to be a landmark gathering for urology and robotic surgery professionals worldwide. From December 11-14, 2024 , leading experts and innovators will convene at Mount Sinai Hospital to explore groundbreaking advancements in research, clinical practices, and surgical techniques. This program offers an unparalleled opportunity for education, collaboration, and innovation in the ever-evolving field of urologic oncology. Attendees can look forward to a dynamic lineup that includes: Over 100 global leaders in urologic oncology will share their expertise, including: This year's symposium is more than an educational event; it's a chance to connect with top professionals, engage in thought-provoking discussions, and experience cutting-edge technology. From live surgical demonstrations to holographic presentations by international experts, the program is designed to push the boundaries of urology and robotic surgery. Don't miss this opportunity to be part of a global gathering of thought leaders and innovators. Register now to secure your place at this extraordinary event. For additional details and registration, visit: https://mountsinaiurologycme.com To relive the excitement, check out highlights from last year's symposium: https://www.youtube.com/watch?v=iRbrhe5kQ-c Join us at Mount Sinai Hospital in New York City this December as we shape the future of urology and robotic surgery! Media Contact: Michael Inocencio , 19143146029, michael.inocencio@mountsinai.org View original content to download multimedia: https://www.prnewswire.com/news-releases/mount-sinai-hospital-to-host-sixth-international-prostate-cancer-symposium-and-world-congress-of-urologic-oncology-302325194.html SOURCE Mount Sinai HospitalThe standard Lorem Ipsum passage, used since the 1500s "Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" Thanks for your interest in Kalkine Media's content! To continue reading, please log in to your account or create your free account with us.

Xavier tries to get right vs. Morgan State before rivalry clash

“John Wick” filmmaker Chad Stahelski recently offered an update on how the Michael B. Jordan-led movie based on Tom Clancy’s “Rainbow Six” property is going. The film will be a follow-up to Amazon Prime Video’s “Without Remorse” film which saw Jordan starring as U.S. Navy SEAL John Kelly. The final moments of that film teased a potential “Rainbow Six” film. Speaking with , Stahelski says the team are taking the right amount of time to ensure it comes together right and so, at present, the project remains in development: “Rainbow Six. It’s a big property. It comes from a big IP. So it’s, you know, the development to do it right. You’ve seen how both video games and in Hollywood are sometimes tricky. It’s always about doing it right and finding the right I, so it gives room for the fans to love what you’re doing. But also you have to give margin to expand out and go. We’re taking our time. A lot of good ideas of being flushed around. It’s been a lot of good development work. We just want to get it right.” Speaking of projects in development, actor Glen Powell has provided an update regarding the long-gestating “Captain Planet” movie. Powell tells that he’s “very, very passionate” about the project: “I want that one to get made, and I feel like we have a very, very strong way into that world and something that I think the world wants to see, but the people that own that property have other ideas and other plans, and that’s fine. Look, I’ll just keep making movies and keep doing what I’m going to do, and eventually, we’ll see if that ever comes back around. But at the end of the day, it’s out of your control.” Powell is also attached to write the film alongside Jono Matt, and no director or other cast are currenlty attached.NowThis made deep cuts to its staff for the second time this year